Evidence map›Paper›PMID 42030330›Full record

ArticlePloS one2026

Curability difference between autochthonous mouse tumors and their transplants in association with immune gene expression.

Hiroshi Tanooka, Chie Kudo-Saito, Fumiko Chiwaki, Masamichi Ishiai, Kouichi Tatsumi, Hiroki Sasaki, Takahiro Ochiya

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hiroshi TanookaCentral Radioisotope Division, National Cancer Center Research Institute, Tokyo, Japan.ORCID https://orcid.org/0000-0001-5167-3756
Chie Kudo-SaitoDepartment of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan.
Fumiko ChiwakiDepartment of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Masamichi IshiaiCentral Radioisotope Division, National Cancer Center Research Institute, Tokyo, Japan.
Kouichi TatsumiBiology Division, National Institute of Radiological Sciences, Chiba, Japan.
Hiroki SasakiDepartment of Translational Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Takahiro OchiyaDepartment of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Compared with transplanted tumors, autochthonous tumors are difficult to cure using experimental radiation therapy in mice. Here we analyzed differences in immune-related gene expression profiles between mouse fibrosarcomas subcutaneously induced by 3-methylcholanthrene (3MC) and their corresponding transplanted tumors. The immune genes examined were Pd1, Pdl1, Pdl2, Cd3d, Cd8a, Cd8b, Ifnγ, Itga2, Gzmb, and Foxp3. Among 12 tumors, one was non-transplantable and showed a benign phenotype with an abundance of DX5+ natural killer cells and CD8+ T cells together with increased IFNγ expression and mRNA levels of all immune genes except for Itga2. The other 11 transplantable tumors showed increased expression of Pd1, Pdl1, Pdl2, Cd3d, Cd8b, and Ifnγ following transplantation into syngeneic mice. These effects of transplantation highlight the relevance of immune gene expression status to the curability of tumors.

Indexed as

FibrosarcomaGene Expression Regulation, NeoplasticAnimalsGene Expression ProfilingInterferon-gammaKiller Cells, NaturalMethylcholanthreneMiceMice, Inbred C57BLNeoplasm TransplantationInterferon-gammaMethylcholanthrene

Identifiers

PMID42030330
PMCPMC13108875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.